CL2003002293A1 - Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. - Google Patents

Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.

Info

Publication number
CL2003002293A1
CL2003002293A1 CL200302293A CL2003002293A CL2003002293A1 CL 2003002293 A1 CL2003002293 A1 CL 2003002293A1 CL 200302293 A CL200302293 A CL 200302293A CL 2003002293 A CL2003002293 A CL 2003002293A CL 2003002293 A1 CL2003002293 A1 CL 2003002293A1
Authority
CL
Chile
Prior art keywords
indazol
treatment
pharmaceutical composition
compounds derived
ocular hypertension
Prior art date
Application number
CL200302293A
Other languages
English (en)
Inventor
B James Chen Meng-Hsin Doherty
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CL2003002293A1 publication Critical patent/CL2003002293A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200302293A 2002-11-08 2003-11-07 Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. CL2003002293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
CL2003002293A1 true CL2003002293A1 (es) 2005-01-14

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302293A CL2003002293A1 (es) 2002-11-08 2003-11-07 Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.

Country Status (22)

Country Link
US (2) US7196082B2 (es)
EP (1) EP1562909B1 (es)
JP (2) JP4456072B2 (es)
KR (1) KR20050072805A (es)
AR (1) AR041991A1 (es)
AU (2) AU2003286884A1 (es)
BR (1) BR0316040A (es)
CA (1) CA2505086C (es)
CL (1) CL2003002293A1 (es)
DO (1) DOP2003000747A (es)
EC (1) ECSP055781A (es)
HR (1) HRP20050409A2 (es)
IS (1) IS7822A (es)
MA (1) MA27497A1 (es)
MX (1) MXPA05004889A (es)
NO (1) NO20052751L (es)
NZ (1) NZ539593A (es)
PE (1) PE20040692A1 (es)
PL (1) PL377172A1 (es)
RU (1) RU2005117627A (es)
TW (1) TWI250873B (es)
WO (2) WO2004043932A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1663987B1 (en) * 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1771170A4 (en) * 2004-07-20 2009-07-08 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
MY151835A (en) * 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof
AU2007227664A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
AU2009308687A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
KR102429220B1 (ko) 2014-04-30 2022-08-04 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 치환 4-페닐피페리딘, 그 제조 및 사용
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (en) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
JPH08511024A (ja) 1993-06-08 1996-11-19 バイディ ファーマシューティカルズ 眼内圧を低下させる方法および組成物
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
EE200200355A (et) 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 retseptori selektiivsed agonistid osteoporoosi raviks
CA2396319A1 (en) 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2001070702A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001070701A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
MXPA03004623A (es) 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
MA27497A1 (fr) 2005-08-01
US7196082B2 (en) 2007-03-27
IS7822A (is) 2005-04-25
AU2003287506B2 (en) 2009-04-23
NO20052751D0 (no) 2005-06-07
CA2505086A1 (en) 2004-05-27
MXPA05004889A (es) 2005-07-22
JP2010006825A (ja) 2010-01-14
US20070129418A1 (en) 2007-06-07
WO2004043933A1 (en) 2004-05-27
HRP20050409A2 (en) 2006-02-28
PL377172A1 (pl) 2006-01-23
US20040097575A1 (en) 2004-05-20
PE20040692A1 (es) 2004-10-08
NZ539593A (en) 2006-12-22
ECSP055781A (es) 2005-09-20
CA2505086C (en) 2009-08-25
JP2006508190A (ja) 2006-03-09
AR041991A1 (es) 2005-06-08
NO20052751L (no) 2005-06-07
DOP2003000747A (es) 2004-05-31
JP5061293B2 (ja) 2012-10-31
AU2003286884A1 (en) 2004-06-03
EP1562909A1 (en) 2005-08-17
US7547720B2 (en) 2009-06-16
RU2005117627A (ru) 2006-01-20
WO2004043932A1 (en) 2004-05-27
AU2003287506B8 (en) 2009-05-28
KR20050072805A (ko) 2005-07-12
BR0316040A (pt) 2005-09-13
EP1562909B1 (en) 2012-06-27
AU2003287506A1 (en) 2004-06-03
TW200501949A (en) 2005-01-16
TWI250873B (en) 2006-03-11
JP4456072B2 (ja) 2010-04-28

Similar Documents

Publication Publication Date Title
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
NO20044054L (no) Administrering av midler for behandling av betennelse
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NO20053041D0 (no) Behandling av diabetes.
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2003001415A1 (es) Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.